Paclitaxel versus docetaxel

of paclitaxel - carboplatin versus docetaxel - carboplatin as first line chemotherapy in stage. Ic-IV epithelial ovarian cancer. Submission date.

In preclinical studies, nab-paclitaxel more effectively suppressed tumor growth than docetaxel (80 versus 29 % inhibition) in breast cancer tumor xenograft models and was associated with less toxicity. Clinical studies confirmed these findings and reported a better therapeutic index with nab-paclitaxel than docetaxel.

Nab-paclitaxel vs sb-paclitaxel or nab-paclitaxel vs docetaxel. Since there were two types of control arm (sb-paclitaxel arm 2,3 or docetaxel arm 4,5,10), we did further subgroup analysis to see

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel Docetaxel and atrasentan versus docetaxel and placebo

Cabazitaxel. Docetaxel. Nab-paclitaxel. Paclitaxel. Vinblastine. Vincristine. Vincristine liposomal. Vinorelbine. Antitumor antibiotics (

Common chemotherapy drug combinations ; Paclitaxel and carboplatin. Paclitaxel and carboplatin ; Docetaxel and carboplatin. Docetaxel and carboplatin.

The key difference between paclitaxel and docetaxel is that paclitaxel has an ester side chain at the C13 position, while docetaxel has a tert-butyl carbonate

by MC Castells Cited by 16Outline Paclitaxel Docetaxel.

The taxoids, paclitaxel (Taxol) and docetaxel (Taxotere), represent a novel class of antineoplastic drugs. Paclitaxel and docetaxel share a similar mechanism of action: the promotion of microtubule assembly and inhibition of microtubule disassembly. The clinical development of paclitaxel was initial